Chymostatin has no apparent beneficial effect on muscular dystrophy in the mdx mouse.
The effect of the cathepsin B inhibitor chymostatin was studied in mice with an X chromosome-linked muscular dystrophy. Treatment for 7 weeks at a daily dose of 1 microgram/g body weight had no apparent beneficial effect: serum creatine kinase levels, histopathology and the activity of muscle cathepsin B were not significantly altered by the treatment.